Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Following a flurry of activity in early 2025, the IPO scene has cooled in the wake of President Trump’s economic tremors.

Metsera Inc. raised $275 million in ... Also on Thursday, Maze Therapeutics Inc. priced an upsized IPO at $16 a share, in the middle of a marketed range, according to a statement.

Its prospectus says that the IPO will fund phase 1 and phase ... in the footsteps of obesity drug developer Metsera and genetic medicines developer Maze Therapeutics, which filed to list on ...

It was the highest total IPO value raised since 2021, with the rebound driven by US Federal Reserve interest rate cuts. The uptick continued into 2025, with Sionna joined by Maze Therapeutics and ...

Odyssey first filed for an IPO in January alongside fellow Massachusetts biotech Sionna Therapeutics. The latter company ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a ...

Belrise Industries IPO Allotment: Belrise Industries IPO allotment has been finalised today. The initial public offering (IPO) of automotive component manufacturer Belrise Industries ended on ...

Belrise Industries IPO listing date is today, May 28, and the shares will be listed on BSE and NSE.(Image: Company Website) Belrise Industries IPO Listing: Belrise Industries shares are set to ...

May 29, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics ... in H2 2025 Raised $140 Million in Gross Proceeds in Upsized IPO in February 2025, Providing Expected Cash Runway into H2 2027 SOUTH SAN ...